表紙SALE
市場調查報告書

羥氯喹及氯喹的全球市場:競爭、預測、機會 - 各種類(注射劑、錠劑)、給藥途徑(口服、經靜脈)、含有量(100mg、250、500㎎㎎)、用途、地區

Global Hydroxychloroquine and Chloroquine Market, By Type (Injectables & Tablets), Route of Administration (Oral v/s Intravenous), Strength (100mg, 250mg & 500mg), Application, Region, Competition, Forecast & Opportunities, 2030

出版商 TechSci Research 商品編碼 932038
出版日期 內容資訊 英文 114 Pages
商品交期: 請詢問到貨日
價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

羥氯喹及氯喹的全球市場:競爭、預測、機會 - 各種類(注射劑、錠劑)、給藥途徑(口服、經靜脈)、含有量(100mg、250、500㎎㎎)、用途、地區 Global Hydroxychloroquine and Chloroquine Market, By Type (Injectables & Tablets), Route of Administration (Oral v/s Intravenous), Strength (100mg, 250mg & 500mg), Application, Region, Competition, Forecast & Opportunities, 2030
出版日期: 2020年04月01日內容資訊: 英文 114 Pages
簡介

全球羥氯喹(台灣又稱羥氯奎寧)及氯喹市場,在預測期間內以強勁的步調成長,至2020年市場規模將擴大2倍。羥氯喹、氯喹可在市場上以Plaquenil、Aralen的商品名取得。這個市場,由於新型冠狀病毒感染疾病(COVID-19)的盛行率上升促進成長。市場規模在2019年估算為約1億4,000萬美元,到2020年將達到2億8,500萬美元。還有美國食品藥物管理局(FDA)對於羥氯喹和氯喹作為新型冠狀病毒感染疾病(COVID-19)的治療藥發行了緊急使用許可。

本報告提供全球羥氯喹及氯喹市場調查,市場概要,各種類、給藥途徑、含有量、用途、地區的市場規模的變化與預測,市場成長要素及課題,市場機會,市場佔有率,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 摘要整理

第4章 客戶的迴響

  • 品牌認知度
  • 給藥途徑
  • 顧客滿意度分析
  • 未滿足需求/課題

第5章 全球羥氯喹及氯喹市場概要

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各類型
      • 注射劑
      • 錠劑
    • 各給藥途徑
      • 口服給藥
      • 經靜脈給藥
    • 各含有量
      • 100mg
      • 250mg
      • 500mg
    • 各用途
      • 類風濕性關節炎
      • 瘧疾
      • 新型冠狀病毒感染疾病(COVID-19)
      • 其他
    • 各企業
    • 各地區
  • 給藥途徑市場地圖

第6章 亞太地區的羥氯喹及氯喹市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各類型
    • 各用途
    • 各給藥途徑
    • 各含有量
    • 各國
  • 市場分析:各國
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國
    • 新加坡

第7章 歐洲的羥氯喹及氯喹市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各類型
    • 各用途
    • 各給藥途徑
    • 各含有量
    • 各國
  • 市場分析:各國
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章 北美的羥氯喹及氯喹市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各類型
    • 各用途
    • 各給藥途徑
    • 各含有量
    • 各國
  • 市場分析:各國
    • 美國
    • 墨西哥
    • 加拿大

第9章 南美的羥氯喹及氯喹市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各類型
    • 各用途
    • 各給藥途徑
    • 各含有量
    • 各國
  • 市場分析:各國
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章 中東、非洲的羥氯喹及氯喹市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各類型
    • 各用途
    • 各給藥途徑
    • 按含有量
    • 各國
  • 市場分析:各國
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第11章 市場動態

  • 成長要素
  • 課題

第12章 市場趨勢

第13章 價格分析

第14章 競爭情形

  • Ipca Laboratories Ltd
  • Zydus Cadila
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Bayer AG
  • Rising Pharma Holdings Inc
  • Abcam plc
  • Mylan N.V
  • Abbott Laboratories
  • Artecef B.V.
  • Uniprix Inc.
  • Recipharm

第15章 策略性推薦事項

目錄
Product Code: 4609

Global hydroxychloroquine and chloroquine market is expected to grow at a robust pace during the forecast period, with the market size expected to double in 2020. Hydroxychloroquine and chloroquine are commonly available in the market under the brand name Aralen and Plaquenil, respectively. Several other formulations of hydroxychloroquine and chloroquine are also available that are sold under different brand names. Chemically, chloroquine is 7-chloro-4-[[4-(diethylamino)-1-methylbutyl] amino] quinoline phosphate (1:2) and is used for the treatment of various diseases such as rheumatoid arthritis, malaria and others.

The global hydroxychloroquine and chloroquine market are driven by the increase in prevalence of COVID-19. In 2019, the market stood at approximately $ 140 million and is expected to reach $ 285 million in 2020. In the recent light of events, FDA issued an Emergency Use Authorization for the treatment of novel coronavirus disease (COVID-19).

Hydroxychloroquine and Chloroquine phosphate belong to the class of antimalarial, amebicides drugs. One of the major applications of Hydroxychloroquine and Chloroquine is for the prevention and treatment of malaria. Globally, Ipca and Cadila are among the top manufacturers of these drugs. The US FDA has recently lifted import alerts on its plants, paving the way for the firms to export the drugs to the US. India is among the major manufacturers of the world's total hydroxychloroquine production and exported worth USD51 million of Hydrochloroquine and Chloroquine and in 2019. China, being the largest manufacturer of APIs, is not producing Hydroxychloroquine because of less cases of malaria.

The global hydroxychloroquine and chloroquine market is segmented based on type, route of administration, strength, application, and region. Based on application, the market can be categorized into rheumatoid arthritis, malaria, COVID-19 and others. In the application segments, COVID-19 is expected to dominate the market due to rising prevalence of this disease.

Furthermore, based on type, the tablet segment is expected to dominate the market due to its cost effectiveness. Among all regions, North America is expected to witness significant growth during the forecast period in the overall hydroxychloroquine and chloroquine market owing to comparatively higher prevalence of COVID-19 .

Major players operating in the global chloroquine market include Ipca Laboratories Ltd, Zydus Cadila, Novartis AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Rising Pharma Holdings Inc, Abcam plc, Mylan N.V, Abbott and others

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2030

Objective of the Study

  • To analyze and forecast the market size of global hydroxychloroquine and chloroquine market.
  • To classify and forecast global hydroxychloroquine and chloroquine market based on type, route of administration, strength, application, company and regional distribution.
  • To identify drivers and challenges for global hydroxychloroquine and chloroquine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global hydroxychloroquine and chloroquine market.
  • To conduct pricing analysis for global hydroxychloroquine and chloroquine market.
  • To identify and analyze the profile of leading players operating in global hydroxychloroquine and chloroquine market.
  • To examine policy & regulatory landscape for global hydroxychloroquine and chloroquine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of hydroxychloroquine and chloroquine manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players operating across the globe.

TechSci Research calculated the market size of global hydroxychloroquine and chloroquine market using a bottom-up approach, wherein data for various segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Hydroxychloroquine and chloroquine manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to chloroquine
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global hydroxychloroquine and chloroquine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Type:

Injectables

Tablets

  • Market, By Route of Administration:

Oral

Intravenous

  • Market, By Strength:

100mg

200mg

250mg

500mg

  • Market, By Application:

Rheumatoid Arthritis

Malaria

COVID-19

Others

  • Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global hydroxychloroquine and chloroquine market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Route of Administration Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

  • 4.1. Brand Awareness (Aided/Unaided)
  • 4.2. Route of Administration Awareness
  • 4.3. Customer Satisfaction Analysis
  • 4.4. Unmet Needs/Challenges

5. Global Hydroxychloroquine & Chloroquine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Injectables, Tablets)
    • 5.2.2. By Route of Administration (Oral v/s Intravenous)
    • 5.2.3. By Strength (100mg,200mg, 250mg, 500mg,)
    • 5.2.4. By Application (Rheumatoid Arthritis, Malaria, COVID-19, Others)
    • 5.2.5. By Company (2019)
    • 5.2.6. By Region
  • 5.3. Route of Administration Market Map

6. Asia-Pacific Hydroxychloroquine & Chloroquine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Route of Administration
    • 6.2.4. By Strength
    • 6.2.5. By Country
  • 6.3. Asia-Pacific: Country Analysis
    • 6.3.1. China Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Strength
    • 6.3.2. India Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Strength
    • 6.3.3. Australia Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Strength
    • 6.3.4. Japan Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Application
        • 6.3.4.2.3. By Route of Administration
        • 6.3.4.2.4. By Strength
    • 6.3.5. South Korea Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Application
    • 6.3.6. Singapore Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.6.1. Market Size & Forecast
        • 6.3.6.1.1. By Value
      • 6.3.6.2. Market Share & Forecast
        • 6.3.6.2.1. By Type
        • 6.3.6.2.2. By Application
        • 6.3.6.2.3. By Route of Administration
        • 6.3.6.2.4. By Strength

7. Europe Hydroxychloroquine & Chloroquine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Route of Administration
    • 7.2.4. By Strength
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Hydroxychloroquine & Chloroquine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Strength
    • 7.3.2. Germany Hydroxychloroquine & Chloroquine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Strength
    • 7.3.3. United Kingdom Hydroxychloroquine & Chloroquine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Strength
    • 7.3.4. Italy Hydroxychloroquine & Chloroquine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Strength
    • 7.3.5. Spain Hydroxychloroquine & Chloroquine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Strength

8. North America Hydroxychloroquine & Chloroquine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Route of Administration
    • 8.2.4. By Strength
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Hydroxychloroquine & Chloroquine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Strength
    • 8.3.2. Mexico Hydroxychloroquine & Chloroquine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Strength
    • 8.3.3. Canada Hydroxychloroquine & Chloroquine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Strength

9. South America Hydroxychloroquine & Chloroquine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Route of Administration
    • 9.2.4. By Strength
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Hydroxychloroquine & Chloroquine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Strength
    • 9.3.2. Argentina Hydroxychloroquine & Chloroquine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Strength
    • 9.3.3. Colombia Hydroxychloroquine & Chloroquine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Strength

10. Middle East and Africa Hydroxychloroquine & Chloroquine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Route of Administration
    • 10.2.4. By Strength
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Hydroxychloroquine & Chloroquine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Strength
    • 10.3.2. Saudi Arabia Hydroxychloroquine & Chloroquine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Strength
    • 10.3.3. UAE Hydroxychloroquine & Chloroquine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Strength
    • 10.3.4. Kuwait Hydroxychloroquine & Chloroquine Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Application
        • 10.3.4.2.3. By Route of Administration
        • 10.3.4.2.4. By Strength

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Pricing Analysis

14. Competitive Landscape

  • 14.1. Ipca Laboratories Ltd
  • 14.2. Zydus Cadila
  • 14.3. Novartis AG
  • 14.4. Teva Pharmaceutical Industries Ltd
  • 14.5. Bayer AG
  • 14.6. Rising Pharma Holdings Inc
  • 14.7. Abcam plc
  • 14.8. Mylan N.V
  • 14.9. Abbott Laboratories
  • 14.10. Artecef B.V.
  • 14.11. Uniprix Inc.
  • 14.12. Recipharm

15. Strategic Recommendations

List of Figures

  • Figure 1: Global Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 2: Global Hydroxychloroquine and Chloroquine Size, By Type (USD Million), 2015-2030F
  • Figure 3: Global Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 4: Global Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 5: Global Hydroxychloroquine and Chloroquine Share, By Region (USD Million), 2015-2030F
  • Figure 6: Global Hydroxychloroquine and Chloroquine Share, By Company (USD Million), 2015-2030F
  • Figure 7: Global Hydroxychloroquine and Chloroquine Attractiveness Index, By Region, By Value, 2015-2030F
  • Figure 8: Global Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration Type, By Value, 2015-2030F
  • Figure 9: North America Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 10: North America Hydroxychloroquine and Chloroquine Size, By Type (USD Million), 2015-2030F
  • Figure 11: North America Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 12: North America Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 13: North America Hydroxychloroquine and Chloroquine Share, By Country (USD Million), 2015-2030F
  • Figure 14: North America Hydroxychloroquine and Chloroquine Attractiveness Index, By Country, By Value, 2015-2030F
  • Figure 15: North America Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 16: United States Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 17: United States Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 18: United States Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 19: United States Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 20: United States Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 21: Canada Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 22: Canada Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 23: Canada Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 24: Canada Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 25: Canada Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 26: Mexico Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 27: Mexico Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 28: Mexico Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 29: Mexico Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 30: Mexico Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 31: Europe Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 32: Europe Hydroxychloroquine and Chloroquine Size, By Type (USD Million), 2015-2030F
  • Figure 33: Europe Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 34: Europe Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 35: Europe Hydroxychloroquine and Chloroquine Share, By Country (USD Million), 2015-2030F
  • Figure 36: Europe Hydroxychloroquine and Chloroquine Attractiveness Index, By Country, By Value, 2015-2030F
  • Figure 37: Europe Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 38: Russia Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 39: Russia Kingdom Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 40: Russia Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 41: Russia Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 42: Russia Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 43: United Kingdom Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 44: United Kingdom Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 45: United Kingdom Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 46: United Kingdom Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 47: United Kingdom Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 48: Italy Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 49: Italy Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 50: Italy Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 51: Italy Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 52: Italy Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 53: Germany Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 54: Germany Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 55: Germany Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 56: Germany Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 57: Germany Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 58: Spain Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 59: Spain Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 60: Spain Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 61: Spain Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 62: Spain Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 63: France Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 64: France Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 65: France Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 66: France Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 67: France Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 68: Asia - Pacific Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 69: Asia - Pacific Hydroxychloroquine and Chloroquine Size, By Type(USD Million), 2015-2030F
  • Figure 70: Asia - Pacific Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 71: Asia - Pacific Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 72: Asia - Pacific Hydroxychloroquine and Chloroquine Share, By Country (USD Million), 2015-2030F
  • Figure 73: Asia - Pacific Hydroxychloroquine and Chloroquine Attractiveness Index, By Country, By Value, 2015-2030F
  • Figure 74: Asia - Pacific Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 75: China Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 76: China Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 77: China Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 78: China Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 79: China Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 80: China Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 81: India Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 82: India Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 83: India Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 84: India Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 85: India Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 86: Australia Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 87: Australia Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 88: Australia Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 89: Australia Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 90: Australia Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 91: Japan Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 92: Japan Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 93: Japan Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 94: Japan Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 95: Japan Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 96: Japan Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 97: Singapore Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 98: Singapore Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 99: Singapore Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 100: Singapore Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 101: Singapore Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 102: South Korea Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 103: South Korea Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 104: South Korea Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 105: South Korea Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 106: South Korea Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 107: South Korea Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 108: Middle East and Africa Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 109: Middle East and Africa Hydroxychloroquine and Chloroquine Size, By Type(USD Million), 2015-2030F
  • Figure 110: Middle East and Africa Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 111: Middle East and Africa Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 112: Middle East and Africa Hydroxychloroquine and Chloroquine Share, By Country (USD Million), 2015-2030F
  • Figure 113: Middle East and Africa Hydroxychloroquine and Chloroquine Attractiveness Index, By Country, By Value, 2015-2030F
  • Figure 114: Middle East and Africa Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 115: Saudi Arabia Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 116: Saudi Arabia Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 117: Saudi Arabia Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 118: Saudi Arabia Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 119: Saudi Arabia Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 120: UAE Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 121: UAE Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 122: UAE Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 123: UAE Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 124: UAE Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 125: UAE Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 126: South Africa Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 127: South Africa Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 128: South Africa Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 129: South Africa Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 130: South Africa Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 131: South Africa Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 132: Kuwait Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 133: Kuwait Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 134: Kuwait Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 135: Kuwait Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 136: Kuwait Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 137: Kuwait Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 138: South America Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 139: South America Hydroxychloroquine and Chloroquine Size, By Type (USD Million), 2015-2030F
  • Figure 140: South America Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 141: South America Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 142: South America Hydroxychloroquine and Chloroquine Share, By Country (USD Million), 2015-2030F
  • Figure 143: South America Hydroxychloroquine and Chloroquine Attractiveness Index, By Country, By Value, 2015-2030F
  • Figure 144: South America Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 145: Brazil Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 146: Brazil Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 147: Brazil Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 148: Brazil Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 149: Brazil Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 150: Brazil Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 151: Argentina Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 152: Argentina Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 153: Argentina Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 154: Argentina Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 155: Argentina Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 156: Colombia Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 157: Colombia Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 158: Colombia Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 159: Colombia Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 160: Colombia Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 161: Colombia Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F